Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Zelboraf (vemurafenib) Tablets – Treatment for Metastatic Melanoma

Drug Name (Brand / Generic)

Zelboraf / Vemurafenib

Company Name / Licensee

Plexxikon and Roche

Therapy Class

BRAF protein inhibitor

Current Indication

Metastatic melanoma and Erdheim-Chester Disease

Market Sector

Cutaneous Oncology

Development Status

Approved in the US, Canada, Europe, Switzerland, Brazil, Israel, Mexico, Australia, and New Zealand
Expand
Close
Close
Close

Go Top